{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-113159","form_type":"8-K","ticker":"NEOG","cik":"0000711377","company_name":"NEOGEN CORP","filed_at":"2022-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.431715+00:00","generated_at":"2026-06-26T05:54:19.262613+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Neogen appoints Doug Jones as COO; VP Genomics Marylinn Munson departs","bullets":["Doug Jones named Chief Operating Officer, a newly created role overseeing worldwide revenues and operations.","Dr. Jason Lilly assumes interim responsibility for North American genomics operations.","Marylinn Munson, former Vice President of Genomics, has left the company.","Jerome Hagedorn (VP North American Operations) and Dr. Lilly will report to Jones; Jones reports to CEO John Adent."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-113159","json":"https://secwatch.observer/filing/0001193125-22-113159.json","markdown":"https://secwatch.observer/filing/0001193125-22-113159.md","text":"https://secwatch.observer/filing/0001193125-22-113159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/711377/000119312522113159/0001193125-22-113159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/711377/000119312522113159/d317850d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T05:54:19.262613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0810dfecda","claim":"Doug Jones was named as Chief Operating Officer at NEOGEN CORP.","evidence_excerpt":"On April 19, 2022, Neogen Corporation (the “Registrant”) announced that Doug Jones was named Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/711377/000119312522113159/0001193125-22-113159-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"named"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"8b9fb0a12d","claim":"Marylinn Munson departed as Vice President, Genomics at NEOGEN CORP.","evidence_excerpt":"Marylinn Munson, former Vice President, Genomics, has left the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/711377/000119312522113159/0001193125-22-113159-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"left"},{"label":"Role","value":"Vice President, Genomics"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}